Abiomed Markets Impella 2.5 Cardiac Assist Device To Cath Labs
This article was originally published in The Gray Sheet
Executive Summary
Abiomed is targeting its Impella 2.5 cardiac assist device at the top 300 interventional cardiology labs in the United States, firm CEO Michael Minogue said in a June 2 conference call announcing the market launch
You may also be interested in...
Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial
Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.
Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial
Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.
TCT In Brief
HORIZONS-AMI: Two-year follow-up results from the 3,000-patient randomized trial show that ischemia-driven target lesion revascularization - the primary endpoint of the study - was 6.8% in patients receiving Boston Scientific's Taxus Express stent compared to 11.6% for those treated with a bare metal stent, firm reports during the Transcatheter Cardiovascular Therapeutics conference in San Francisco. For the secondary endpoint, target vessel revascularization, the rates for the Taxus Express and bare metal stent groups were 8.9% and 13.3%, respectively. The rate of major adverse cardiac events at two years was 11% for the drug-eluting stent and 11.2% for the bare metal stent. HORIZONS-AMI is designed to assess the safety and efficacy of Taxus Express in high-risk acute myocardial infarction patients